EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B)

Meiko Nishimura iD, Takahiro Kogawa, Keiji Sugiyama, Yukinori Ozaki, Yuko Tanabe, Chikako Funasaka, Sasagu Kurozumi, Akiyo Yoshimura, Tsutomu Iwasa, Hitomi Sakai, Mitsunori Morita, Satomi Watanabe und 8 weitere

Breast Cancer Research and Treatment · 2026

DOI: 10.1007/s10549-026-08031-2 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Breast Cancer Research and Treatment, 2026. Verfasst von Meiko Nishimura und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Kotou-ku, Tokyo, 135-8550, …. Hauptthemen laut MEDLINE: Aminopyridines, Benzimidazoles, Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminopyridinesBenzimidazolesBreast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleErb-b2 Receptor Tyrosine KinasesMiddle AgedReceptors, EstrogenAdultAgedReceptors, ProgesteroneRetreatmentFulvestrantNeoplasm MetastasisDisease Progression

Stichwörter der Autor:innen

AbemaciclibCDK 4/6 inhibitorHormone receptor-positive HER2 negative breast cancer

Substanzen

abemaciclibAminopyridinesBenzimidazolesErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenERBB2 protein, humanReceptors, ProgesteroneFulvestrant

Autor:innen und Institutionen

  • Department of Breast Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Kotou-ku, Tokyo, 135-8550, Japan. meiko.nishimura@jfcr.or.jp.
  • Division of Early Clinical Development for Cancer, Department of Advanced Medical Development, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Kotou-ku, Tokyo, 135-8550, Japan. takahir…
  • Department of Medical Oncology, NHO Nagoya Medical Center, Aichi, Japan.
  • Department of Breast Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Kotou-ku, Tokyo, 135-8550, Japan.
  • Department of Clinical Oncology, Toranomon Hospital, Tokyo, Japan.
  • Department of Experimental therapeutics, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

ORCID-Profile: Meiko Nishimura

Zitieren

APA

Nishimura, M., Kogawa, T., Sugiyama, K., Ozaki, Y., Tanabe, Y., Funasaka, C., Kurozumi, S., Yoshimura, A., Iwasa, T., Sakai, H., Morita, M., Watanabe, S., Fujii, T., Yamamoto, M., Tsuji, Y., Terada, M., Ota, T., Tokunaga, S., Shimokawa, M., & Takano, T. (2026). Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B). Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08031-2

Vancouver

Nishimura M, Kogawa T, Sugiyama K, Ozaki Y, Tanabe Y, Funasaka C, et al. Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B). Breast Cancer Research and Treatment. 2026. doi:10.1007/s10549-026-08031-2

BibTeX
@article{Nishimura2026,
  author = {Nishimura, Meiko and Kogawa, Takahiro and Sugiyama, Keiji and Ozaki, Yukinori and Tanabe, Yuko and Funasaka, Chikako and Kurozumi, Sasagu and Yoshimura, Akiyo and Iwasa, Tsutomu and Sakai, Hitomi and Morita, Mitsunori and Watanabe, Satomi and Fujii, Takaaki and Yamamoto, Mitsugu and Tsuji, Yasushi and Terada, Mitsuo and Ota, Takayo and Tokunaga, Shinya and Shimokawa, Mototsugu and Takano, Toshimi},
  title = {Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B)},
  journal = {Breast Cancer Research and Treatment},
  year = {2026},
  doi = {10.1007/s10549-026-08031-2}
}
Kostenlos starten →